Compare Hershey Co (HSY) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Summit Therapeutics Inc — how do they compare? Hershey Co trades at $184.8 (market cap $36.56B), while Summit Therapeutics Inc trades at $15.16 (market cap $12.06B). The key difference: Hershey Co is far larger — about 3× Summit Therapeutics Inc's market cap, and Hershey Co pays a 3.19% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HSY | SMMT | |
|---|---|---|
Market Cap | $36.56B | $12.06B |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $26.98 |
52-Week Low | $162.31 | $12.55 |
Enterprise Value | $41.70B | $11.39B |
Dividend Yield | 3.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $184.19, up 0.79% with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats with Q2 2026 EPS of $1.90 exceeding expectations by 33%, while revenue growth remains steady at $11.69 billion for 2025. Technical indicators show bullish momentum with the current price near resistance at $184, supported by positive moving average signals. The company maintains robust profitability with 38.38% gross margins and 32.81% ROE, though net income declined to $883 million in 2025 from previous highs.
HSY presents a favorable risk-reward profile with analyst consensus target of $196.78 offering 7% upside potential. Recent margin recovery from favorable cocoa contracts and dividend growth support bullish sentiment, though volume declines and competitive pressures in salty snacks remain concerns. With 68.57% of analysts maintaining Hold ratings, the stock offers steady growth potential but requires monitoring of consumer demand trends and input cost management.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
